Despite Recent Bad News, Here's Why CRISPR Is Primed to Explode

Despite Recent Bad News, Here's Why CRISPR Is Primed to Explode

Source: 
Motley Fool
snippet: 

CRISPR Therapeutics' (NASDAQ:CRSP) stock took a hard hit when it disclosed on Oct. 21 that a patient in its Carbon phase 1 clinical trial for relapsed non-Hodgkin's lymphoma died unexpectedly earlier this month. But this unfortunate news doesn't diminish the company's immense potential stemming from its advanced gene-editing technology. Nor will it throw any of CRISPR's clinical trials off track. In fact, with these preliminary results in hand, CRISPR has two powerful things in its favor that investors should know.